艾迪药业进一步并购南大药业股权 夯实人源蛋白领域布局

Core Viewpoint - The acquisition of an additional 22.2324% stake in Nanjing Nanda Pharmaceutical by Aidi Pharmaceutical strengthens its control and supports its integrated strategy in human-derived protein production and formulation [1][2]. Group 1: Acquisition Details - Aidi Pharmaceutical announced the acquisition of 22.2324% of Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [1]. - This acquisition is aimed at solidifying control and enhancing the implementation of the company's integrated strategy in human-derived protein [2]. Group 2: Strategic Benefits - The acquisition is expected to reinforce strategic management, enhance resource synergy, and improve operational efficiency by integrating production, channels, and platforms [2]. - The financial performance of Nanjing Nanda Pharmaceutical has shown steady growth, with revenues of 299 million yuan and net profits of 51.5177 million yuan in 2024, and 262 million yuan in revenue with net profits of 55.8111 million yuan from January to October 2025 [2]. Group 3: R&D Achievements - Following the previous acquisition, Aidi Pharmaceutical and Nanjing Nanda Pharmaceutical have successfully developed two human-derived protein drugs, AD108 and ADB116, which have received IND approval [3][4]. - These drugs are designed to meet clinical needs, with AD108 offering a subcutaneous delivery method and ADB116 providing a rapid intravenous administration option for acute ischemic stroke [4]. Group 4: Market Potential - The human-derived protein market, particularly for ischemic stroke treatment, is significant, with approximately 3.4 million new stroke cases annually in China, 80% of which are ischemic strokes [5]. - The market for ischemic stroke treatments is projected to grow, with a 2023 market size of approximately 12.9 billion yuan, indicating substantial opportunities for Aidi Pharmaceutical's new products [5]. Group 5: Future Outlook - Aidi Pharmaceutical plans to leverage this acquisition to deepen resource integration with Nanjing Nanda Pharmaceutical, accelerating the development of its human-derived protein pipeline [6]. - The company aims to capitalize on industry growth and enhance its position in the human-derived protein sector, contributing to high-quality development in the biopharmaceutical industry [6].